Loading...

Ann F Mohrbacher, MD

TitleAssociate Professor of Clinical Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
Address1441 Eastlake Ave.
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 865 3924
vCardDownload vCard
    Other Positions
    TitleMedical Director, Autologous Bone Marrow Transplant


    Collapse Biography 
    Collapse Awards and Honors
    Harvard University 1983A.B. Magna Cum Laude
    Harvard University1983Scholarship
    American Society of Clinical Oncology1995Career Development Award

    Collapse Overview 
    Collapse Overview
    Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.


    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Punwani N, Merin N, Mohrbacher A, Yaghmour G, Sano A, Ramezani L, Chaudhary PM, Ramsingh G. Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia. Leuk Res Rep. 2018; 9:18-20. PMID: 29556468.
      View in: PubMed
    2. Su DW, Pasch W, Costales C, Siddiqi I, Mohrbacher A. Asian-variant intravascular large B-cell lymphoma. Proc (Bayl Univ Med Cent). 2017 Apr; 30(2):186-189. PMID: 28405077.
      View in: PubMed
    3. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher A, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. PMID: 27587788.
      View in: PubMed
    4. Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 06 09; 127(23):2833-40. PMID: 27091875; PMCID: PMC4900953.
    5. Aldoss I, Pullarkat V, Patel R, Watkins K, Mohrbacher A, Levine AM, Douer D. An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. Med Oncol. 2013 Dec; 30(4):744. PMID: 24135867.
      View in: PubMed
    6. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5. PMID: 22291084; PMCID: PMC4874204.
    7. Zonder JA, Mohrbacher A, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012 Jul 19; 120(3):552-9. PMID: 22184404; PMCID: PMC4467882.
    8. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher A, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. PMID: 21517811; PMCID: PMC3272081.
    9. Bernstein I, Byun HM, Mohrbacher A, Douer D, Gorospe G, Hergesheimer J, Groshen S, O'Connell C, Yang AS. A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. PMID: 20861661.
      View in: PubMed
    10. Reece DE, Sullivan D, Lonial S, Mohrbacher A, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011 Jan; 67(1):57-67. PMID: 20306195; PMCID: PMC3951913.
    11. Pullarkat V, Veliz L, Chang K, Mohrbacher A, Teotico AL, Forman SJ, Slovak ML. Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol. 2007 May; 60(5):562-4. PMID: 17513515; PMCID: PMC1994540.
    12. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006 Feb 15; 106(4):848-58. PMID: 16404741.
      View in: PubMed
    13. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther. 2005; 7 Suppl 3:S19-25. PMID: 15960818; PMCID: PMC2833973.
    14. Mohrbacher A, Gregory SA, Gabriel DA, Rusk JM, Giles FJ. Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer. 2002 May 15; 94(10):2645-52. PMID: 12173332.
      View in: PubMed
    15. Nguyen TT, Mohrbacher A, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, Yu MC, Lübbert M, Jones PA. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000 May 01; 95(9):2990-2. PMID: 10779450.
      View in: PubMed
    16. Douer D, Ramezani L, Mohrbacher A, Khan A, Groshen S, Levine AM, Anderson WF. The influence of patient-related factors on ex vivo retroviral-mediated gene transfer into mobilized peripheral blood myeloid progenitors. Hum Gene Ther. 1998 May 01; 9(7):1061-8. PMID: 9607417.
      View in: PubMed
    17. Uchiyama H, Barut BA, Mohrbacher A, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993 Dec 15; 82(12):3712-20. PMID: 8260708.
      View in: PubMed